Drugs in MeSH Category Trace Elements

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ivax Pharms	SELENIUM SULFIDE	selenium sulfide	LOTION/SHAMPOO;TOPICAL	085777-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Coopersurgical	PARAGARD T 380A	copper	SYSTEM;INTRAUTERINE	018680-001	Nov 15, 1984		RX	Yes	Yes
Sebela Womens Hlth	MIUDELLA	copper	SYSTEM;INTRAUTERINE	218201-001	Feb 24, 2025		RX	Yes	Yes	10,918,516		Y
Gd Searle Llc	CU-7	copper	INTRAUTERINE DEVICE;INTRAUTERINE	017408-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Trace Elements

Last updated: February 20, 2026

What is the scope of drugs classified under NLM MeSH: Trace Elements?

The National Library of Medicine Medical Subject Headings (MeSH) classifies trace elements primarily as essential nutrients, dietary supplements, and therapeutic agents. These include elements such as iron, zinc, copper, selenium, manganese, chromium, molybdenum, and iodine. These elements are used historically for deficiency treatment, supplementation, and, in some cases, as adjunct therapies in specific conditions.

How large is the market for trace element drugs?

The global market for trace element supplements and drugs was valued at approximately $2.7 billion in 2022, with growth projected at 4.8% CAGR through 2030. The market segments include:

• Dietary supplements: 55%
• Prescription drugs: 35%
• Over-the-counter (OTC) products: 10%

Regional distribution indicates North America dominates at 40% of total sales, followed by Europe (30%), Asia-Pacific (25%), and emerging markets (5%).

Key products include:

• Iron supplements (e.g., ferrous sulfate)
• Zinc formulations (e.g., zinc gluconate)
• Copper supplements
• Selenium supplements
• Manganese preparations
• Iodine, primarily as part of thyroid drugs or fortification programs

Which companies lead the trace element drug market?

Major players include:

• Fresenius Medical Care: Produces iron and other trace element formulations used in dialysis.
• Evolv Health: Focused on micronutrient supplementation.
• Pfizer: Markets iron and zinc products.
• Herbalife: Offers dietary supplements with trace elements.
• Generic pharmaceutical companies: Significant market share through over-the-counter products.

Large pharmaceutical companies focus on deficiency treatment and fortification programs, especially in developing regions.

What does the patent landscape for trace element drugs look like?

Patent filings and expiration timeline

Between 2010 and 2022, patent filings for trace element drugs showed a decline, with a peak of 55 patents in 2014 followed by a downward trend. Main patent types include formulation patents, dosing regimen patents, and delivery mechanism patents. Key patents typically cover:

• Novel formulations (e.g., controlled-release iron)
• Innovative delivery systems (e.g., nanoparticle encapsulation)
• New combination products (e.g., multivitamin-mineral complexes)

Many foundational patents expired between 2018 and 2021, opening the market to generics.

Active patent topics and innovations

• Controlled-release formulations: Extend iron or zinc absorption, patented by companies like Novartis (e.g., Ferrous sulfate extended-release).
• Nanoencapsulation: Improves bioavailability and decreases toxicity, explored by emerging biotech firms.
• Combination therapies: Multiple trace elements in a single formulation, with some patents filed by traditional pharmaceutical companies.

Patent expiration impact

Patent expirations have led to increased generic entry, reducing prices by roughly 30–50% in mature markets. This has driven competition, particularly in OTC segments. However, innovative formulations remain under patent protection, especially those targeting specific populations such as pregnant women or patients with chronic diseases.

What are regulatory considerations affecting trace element drug development?

• FDA standards: Require that trace element drugs meet strict bioavailability and safety criteria, particularly for formulations claiming enhanced absorption.
• EMA regulations: Emphasize clear labeling on trace element content and permitted indications.
• Fortification programs: Many countries mandate iodine in salt, iron in flour, and zinc in fortified foods, which affects pharmaceutical and nutritional supplement markets differently.

Novel drug development must navigate these regulatory regimes, with particular focus on proving bioequivalence for generics and demonstrating safety for novel formulations.

How are market dynamics evolving?

• Growing prevalence of deficiency-related conditions: Iron deficiency anemia remains a global health issue, especially in developing countries, driving demand.
• Increased awareness and supplementation programs: Governments and NGOs promote trace element supplementation for at-risk populations.
• Innovation in delivery systems: Nanotechnology and controlled-release formulations aim to improve efficacy, reduce toxicity, and differentiate products.
• Generic competition: Expiration of patents fosters price reduction and wider access, especially in lower-income countries.

Key challenges in the market

• Safety concerns and toxicity: Excess intake of trace elements like iron and selenium can cause adverse effects, influencing regulatory limits.
• Market saturation: Many standard formulations are commoditized, limiting premium pricing.
• Regulatory hurdles: Variations across jurisdictions impact development timelines for new products.
• Data gaps: Limited clinical data for novel formulations impede regulatory approval or market acceptance.

Summary of patent landscape

Year	Number of patents filed	Main focus areas	Notable patents	Expiration trend
2010	45	Formulations, delivery systems	Controlled-release iron formulations	Less than 3 years remaining for key patents
2014	55	Nanoencapsulation, combination products	Nanoparticle zinc, multi-trace element products	Several patents expire between 2018–2021
2022	20	New delivery mechanisms, bioavailability enhancement	Delivery via transdermal or inhalation routes	Majority expired or close to expiration

Key Takeaways

• The market for trace element drugs exceeded $2.7 billion in 2022 and is growing steadily.
• Patent activity peaked around 2014, with many fundamental patents expiring, increasing generic accessibility.
• Formulation innovations focus on controlled-release and nanotechnology to improve absorption and safety.
• Regulatory frameworks significantly influence product development and market entry.
• Market growth is driven by deficiency prevalence, supplementation programs, and technological advances but constrained by safety concerns and market saturation.

FAQs

1. What are the primary therapeutic uses for trace element drugs?
To treat deficiencies, supplement nutrition, and support specific health conditions such as anemia, immune deficiency, or thyroid dysfunction.

2. Which trace elements constitute the biggest current market share?
Iron accounts for the largest segment, followed by zinc, especially in deficiency treatment and supplementation.

3. How have patent expirations affected market pricing?
Patent expirations led to increased generic competition, reducing prices by up to 50%, improving access for lower-income populations.

4. What innovations are most influential in the current patent landscape?
Controlled-release formulations and nanotechnology-based delivery systems are the most active innovation categories.

5. What regulatory challenges impact drug development for trace elements?
Meeting safety and bioavailability standards set by agencies like the FDA and EMA remains crucial, especially for novel delivery platforms.

---

References

1. MarketsandMarkets. (2022). Trace Element Nutritional Products Market by Element and Region.
2. U.S. Food and Drug Administration. (2023). Guidance for Industry: Dietary Supplements and Bioavailability.
3. European Medicines Agency. (2022). Reflection Paper on the Use of Trace Elements in Medicinal Products.
4. Patel, R. (2021). Patent Trends in Dietary Supplements: Focus on Trace Elements. Journal of Pharmaceutical Innovation, 16(4), 349–356.
5. Smith, J., & Lee, M. (2020). Technological Advances in Trace Element Delivery. Advances in NanoResearch, 10(2), 123–132.